Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best healthcare stocks with the highest upside. Goldman Sachs initiated coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) on October 7 with a Buy rating, assigning the stock a $125 price target. Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? The analyst told investors that Goldman Sachs expects Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) Vykat XR to become a “foundational treatment” for Prader-Willi syndrome. According to the firm, the drug s ...